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Abstract. The aim of this study was to investigate the predic-
tive impact of polymorphisms in the HIF-1α gene on the 
response to chemoradiotherapy (CRT) in rectal cancer. This 
study included two cohorts of patients with locally advanced 
rectal cancer receiving long-course CRT. The HIF-1α C1772T 
(rs11549465), G1790A (rs11549467) and c*191T>C (rs2057482) 
polymorphisms were investigated in the test cohort (n=65), 
and HIF-1α c*191T>C was analysed in the validation cohort 
(n=198). No correlations were identified between the polymor-
phisms and clinicopathological factors. The HIF-1α C1772T and 
HIF-1α G1790A polymorphisms demonstrated no correlation 
with tumour response to CRT in the test cohort. The HIF-1α 
c*191T>C CC genotype was marginally associated with a higher 
rate of complete tumour response (P=0.05) in the test cohort, 
while the HIF-1α c*191T>C CC genotype was associated with 
a poor tumour response (P=0.03) in the validation cohort. In 
conclusion, these results suggest that HIF-1α polymorphisms 
have no value as predictors of response to neoadjuvant CRT in 
rectal cancer. The results of the HIF-1α c*191T>C in two cohorts 
differ and emphasise the importance of biomarker validation.
Introduction
Long‑course chemoradiotherapy (CRT) followed by meso-
rectal excision is now considered as a standard treatment for 
locally advanced rectal cancer. Compared with radiation alone, 
CRT reduces the risk of local recurrence; however, the impact 
on overall survival is dubious (1). CRT is only beneficial to a 
subgroup of patients; thus, a more efficient patient selection for 
the combined treatment is required. A minor group of patients 
experiences complete tumour response, which may be verified 
by pathological examination of the surgical specimens. These 
patients may avoid surgery involving a permanent stoma (2,3). 
The current situation requires markers which are able to predict 
the complete tumour response with regards to patient selection.
Several markers of potentially predictive value have been 
studied, but to date, none have passed clinical validation, 
which is a hallmark for clinical routine application. Tumour 
hypoxia is a well‑established phenomenon in the development 
of malignant tumours (4), and the importance of hypoxia to the 
effect of radiotherapy has been acknowledged for decades (5). 
Markers associated with hypoxia are evident candidates as 
predictors of response to CRT.
Hypoxia‑inducible factor 1 (HIF‑1) is a central protein 
involved in the cellular adaption to hypoxia. HIF-1 is a 
heterodimeric transcription factor consisting of HIF-1α 
and HIF-1β subunits (6), which induce the transcription of 
numerous genes that are necessary for the cellular response 
to hypoxia (7). Oxygen tension is essential for the activation 
of HIF-1. The presence of oxygen leads to the degradation of 
HIF-1α, while hypoxic conditions allow HIF-1α to bind to 
HIF-1β and become an active transcription‑inducer (8). HIF‑1α 
has been associated with aggressive tumour growth (4) and 
poor prognosis in several types of cancer, including colorectal 
cancer (9).
HIF-1 is an important mediator of hypoxia-induced 
radioresistance, and studies have demonstrated that cell lines 
with impaired HIF‑1 activation ability are more sensitive to 
radiotherapy compared with cells with intact HIF-1 activation 
ability (10-12). Additionally, the in vitro response of tumour 
cells to 5‑fluorouracil (5FU) appears to be dependent on 
HIF-1 (13).
Only a small number of studies have investigated the 
possible predictive value of HIF‑1α in CRT of rectal cancer. In 
a previous study, we identified no correlation between immu-
nohistochemical (IHC) expression of the HIF-1α protein and 
tumour response (14). Another study observed an association 
between the staining intensity of HIF‑1α and poor response; 
however, this association was not significant when comparing 
HIF-1α positive tumours and HIF-1α negative tumours (15). 
The gene expression of HIF-1α was studied by Toiyama et al 
who identified an association between high HIF‑1α gene 
expression and poor tumour response following short-course 
CRT (16), while Saigusa et al identified no correlation between 
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HIF-1α gene expression and tumour response (17). To date, 
the results presented of HIF-1α protein and gene expression in 
relation to rectal cancer CRT have been inconclusive. The role 
of germline polymorphisms in the HIF-1α gene in relation to 
CRT remain to be explored.
The HIF-1α gene is located on chromosome 14 and a 
number of single nucleotide polymorphisms (SNPs) have 
been identified in the HIF‑1α gene. The most frequently 
investigated polymorphisms are the C1772T (rs11549465), 
which comprises an amino acid change from proline to serine 
at position 582, and the G1790A (rs11549467), which results 
in the substitution of alanine with threonine at position 588. 
These polymorphic variants have demonstrated functional 
importance by increasing the transcriptional activity in vitro 
under normoxic and hypoxic conditions, and have been associ-
ated with increased microvessel density in patients with head 
and neck cancer (18).
Few studies have suggested a correlation between the 
above mentioned polymorphisms and the risk of colorectal 
cancer (19,20); while one study demonstrated an association 
between HIF‑1α c*191T>C (rs2057482) and the risk of rectal 
cancer (21). No previous studies have investigated the possible 
importance of these polymorphisms for rectal cancer CRT.
The aim of this study was to investigate the predictive 
impact of germline C1772T, G1790A and c*191T>C polymor-
phisms in the HIF-1α gene on the response to CRT in locally 
advanced rectal cancer.
Patients and methods
Patients. The study included two cohorts treated with 
long-course CRT at the Department of Oncology (Vejle 
Hospital, Denmark). Inclusion criteria were patients with 
T3-T4 N0-N2 M0 histopathologically verified adenocar-
cinoma of the rectum, located <10 cm from the anal verge 
and with a distance of <5 mm to the mesorectal fascia. 
Pre-treatment staging was performed based on clinical 
examinations and magnetic resonance imaging (MRI) of the 
pelvis. Furthermore, computerised tomography (CT) of the 
chest and abdomen, or a chest X‑ray and ultrasound of the 
liver were conducted to exclude distant metastases. Patients 
with available archival blood samples were included in this 
study.
The test cohort included 65 patients who were treated 
according to two previously published studies (22,23) with 
long‑course CRT between 2002 and 2005, comprising conven-
tional radiotherapy of 60 Gy/30 fractions and supplemented 
by a brachytherapy boost of 5 Gy. Concomitant chemotherapy 
consisting of 300 mg/m2 UFT (uracil‑tegafur; molar ratio 4:1) 
and 22.5 mg isovorin was administered to patients on treat-
ment days.
The validation cohort included 203 patients who were 
treated according to a phase III randomised study between 2005 
and 2009, comprising conventional CRT of 50.4 Gy/28 frac-
tions with or without 10 Gy/2 fractions of brachytherapy. 
Concomitant chemotherapy was administered as previously 
described (24) Patient consent was obtained prior to inclusion 
in the studies (22‑24) which were approved by the local ethics 
committee of The Regional Scientific Ethical Committee for 
Southern Denmark.
Response evaluation. Total mesorectal excision surgery was 
scheduled 8 weeks following the end of CRT. Pathological 
response was evaluated in the surgical specimens according 
to Mandard's Tumour Regression Grade (TRG) (25). The 
endpoints of this study were complete tumour response, 
defined as the absence of viable residual tumour cells in the 
resected surgical specimens (TRG 1) and complete patho-
logical response (CPR) defined as TRG 1 combined with no 
lymph node metastases (ypT0 and ypN0).
Analysis of SNPs. The investigated SNPs were selected 
as potentially clinically relevant polymorphisms based on 
previous studies (18‑21,26‑28). Genomic DNA was purified 
from whole blood using the NucloeSpin® Tissue method 
according to the manufacturer's instructions (NucleoSpin 
Tissue, Macherey‑Nagel, Germany; Feb 2001/Rev. 02), or 
the Maxwell robot using 300 µl whole blood (elution was 
performed in 350 µl) and the Maxwell® 16 Blood DNA purifi-
cation kit (AS1010; Promega, Madison, WI, USA), according 
to the manufacturer's instructions.
Table I. Clinicopathological parameters of rectal cancer 
patients.
 Test Validation
Clinicopathological cohort, cohort,
parameters n (%) n (%) P-value
Gender
  Male 45 (69) 126 (62) NS
  Female 20 (31)    77 (38)
Age (years)
  Median 63.4 63.3
  Range 40.4-77.7 35.5-78.8
cT classification
  3 62 (95) 168 (83) 0.01
  4   3 (5)   35 (17)
cN classification
  - 18 (28)   23 (11)   0.003
  + 47 (72) 180 (89)
TRG
  1 19 (29)   39 (19) NSa
  2 15 (23)   28 (14)
  3 29 (45) 120 (59)
  4 2 (3) 16 (8)
ypN classification
  - 48 (74) 138 (68) NS
  + 17 (26)   65 (32)
CPR (TRG 1 and ypN0)
  Yes  16 (25)   35 (17) NS
  No 49 (75) 168 (83)
Total 65 203
aTRG 1 vs. TRG 2‑4. TRG, tumour regression grade; CPR, complete 
pathological response; NS, not significant (P>0.05).
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In the test cohort, the SNP analyses were conducted 
in-house. The HIF-1α c*191T>C was analysed using the 
Taqman assay (c_8549084_20) with 2 µl DNA and genotyping 
master mix in a total volume of 20 µl, using the 7900 HT 
Real-Time polymerase chain reaction (PCR) system (Applied 
Biosystems, Foster City, CA, USA) on a standard programme 
of genotyping.
The HIF-1α C1772T and G1790A were analysed by 
sequencing. Initially, PCR was performed with 2 µl DNA, 
0.5 µM primer, 2.0 mM MgCl2, 0.2 mM deoxyribonucleotide 
triphosphate (dNTP) and 0.04 units Taq Gold with buffer 
(Applied Biosystems), in a total volume of 25 µl with cycling 
conditions as follows: 95˚C for 10 min, and 40 cycles at 95˚C for 
40 sec, 54˚C for 40 sec and 72˚C for 40 sec, followed by 72˚C 
for 10 min. The PCR products were treated with ExoSAP-IT 
(USB Corp., Cleveland, OH, USA), to remove unused primers 
and nucleotides. PCR sequencing was then conducted with 
1 µl PCR product, 1.5 µl Big Dye sequencing buffer, 1 µl 
terminator RR mix, and 1 µl 1.6 µM forward or reverse primer, 
in a total volume of 10 µl with cycling conditions as follows: 
96˚C for 1 min, and 25 cycles at 96˚C for 10 sec, 50˚C for 5 sec 
and 60˚C for 4 min.
The primers (forward, 5'-GAC TTG GAG ATG TTA GCT 
CCC TA‑3'; reverse, 5'‑TTC TTG TAT TTG AGT CTG CTG 
GA-3') were designed in-house. After 45 µl SAM solution and 
10 µl Big Dye Terminator were added to the 10 µl sequencing 
PCR product, the sequencing product was analysed using a 
3130 Genetic Analyzer (Applied Biosystems). Sequences were 
analysed using Sequencing Analysis Software version 5.2 
(Applied Biosystems). In each method, controls were analysed 
alongside the samples.
In the validation cohort, purified DNA was sent to 
KBioscience (Hoddesdon, Hertfordshire, UK; http://www.
kbioscience.co.uk) who conducted the SNP genotyping using 
a KASPar genotyping system, designed and validated by 
KBioscience. Data were inspected using their SNPviewer PC 
tool.
Statistical analysis. Fisher's exact test was used to analyse the 
association between clinicopathological parameters, TRG and 
the polymorphisms, as well as the differences in these param-
eters between the two cohorts. Confidence intervals (CIs) of 
the proportions of polymorphisms were calculated using the 
Wilson score method. All tests were two‑sided and P<0.05 
was considered to indicate a statistically significant difference. 
NCSS 2007 statistical software (NCSS, Kaysville, UT, USA) 
was used for all analyses.
Results
Patient characteristics. Clinicopathological characteristics 
of the two cohorts are presented in Table I. The majority of 
patients in both cohorts had a T3 tumour, while there was 
a higher frequency of T4 tumours in the validation cohort 
(P=0.01). The rate of patients without clinical lymph node 
metastases also varied (P=0.003), but there was no difference 
with regard to complete tumour response (TRG 1) or frequency 
of CPR between the two cohorts.
Polymorphisms. HIF-1α c*191T>C, HIF-1α C1772T and 
HIF-1α G1790A polymorphisms were analysed in 65 patients 
in the test cohort, and the HIF-1α c*191T>C polymorphism 
was successfully analysed in 198 of the 203 patients in the 
validation cohort.
The distribution of the three polymorphisms in the HIF1α 
gene is shown in Table II. All polymorphisms were in agreement 
Table II. Distribution of the HIF‑1α polymorphisms and the various genotypes.
 Test cohort Validation cohort
 -------------------------------------------------------------- ---------------------------------------------------------------
HIF-1α polymorphisms n % (95% CI) n % (95% CI)
HIF-1α c*191T>C
  CC 51   78 (67-87) 153   75 (69-81)
  CT 13   20 (12-31)   41   20 (15-26)
  TT   1    2 (0.3-8)     4 2 (1-5)
  ND       5 2
HIF-1α C1772T
  CC 57   88 (78-94)
  CT   8 12 (6-22)
  TT   0
HIF-1α G1790A
  GG 64     98 (92-100)
  GA   1    2 (0.3-8)
  AA   0
Total 65  203
Sum of the percentages does not always equal 100% due to the rounding of data. HIF‑1α, hypoxia‑inducible factor‑1α; CI, confidence interval; 
ND, not determined.
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with the Hardy Weinberg equilibrium. The homozygous TT 
genotype was rare in the HIF-1α c*191T>C and HIF-1α C1772T 
polymorphisms. The same applied to the GA and AA genotypes 
of the HIF-1α G1790A polymorphism. No association was iden-
tified between the three polymorphisms and clinicopathological 
factors. Additionally, there was no correlation between the 
HIF-1α C1772T or HIF-1α G1790A polymorphism and response 
to CRT as measured by TRG and CPR in the test cohort, and 
consequently they were not analysed in the validation cohort.
Table III shows the association of the HIF‑1α c*191T>C 
polymorphism with TRG and CPR. In the test cohort, a high 
rate of complete tumour regression was observed in patients 
with the CC homozygous genotype (35%) compared with the 
CT/TT genotype (7%) (P=0.05). Similarly, CPR was observed 
in 29 and 7% of patients with CC and CT/TT genotype, 
respectively; however, this was not significant (P=0.16). In the 
validation cohort there appeared to be a statistically signifi-
cantly lower rate of TRG 1 in patients with the CC genotype 
(16%) compared with the CT/TT genotype (31%; P=0.03). 
Similarly, CPR was observed in 16 and 24% of patients with 
the CC and CT/TT genotype, respectively; however, this was 
not significant (P=0.19).
Discussion
Numerous biomarkers have been studied in the search for a 
prediction of CRT response in rectal cancer. To date, none 
have proven to be valid for clinical application. SNPs are 
attractive due to their stable nature and inexpensive analysis 
costs. Additionally, blood cells are easily accessible material.
To the best of our knowledge, the polymorphisms of 
the HIF-1α gene have not been studied with regard to CRT; 
however, HIF-1α protein expression has been subject to inves-
tigation in a number of malignant tumour types. In patients 
with head and neck cancer, previous studies have indicated a 
predictive importance of IHC HIF-1α protein expression in 
relation to radiotherapy (29-31), which translated into poor 
survival. Similarly, IHC HIF-1α expression has been associ-
ated with poor outcome following radical radiotherapy in 
patients with cancer of the cervix uteri (32,33).
Based on previous studies, it is justified to investigate the 
possible predictive value of HIF‑1α in CRT of rectal cancer. 
However, the few studies on IHC expression of HIF-1α and 
tumour response, including recent data from our own group, 
have revealed conflicting results, and the same applies to 
studies investigating HIF-1α gene expression levels of the 
marker (14‑17). Therefore, in the present study, we investigated 
polymorphisms of the HIF-α gene in patients with rectal cancer.
In contrast to previous data suggesting a correlation between 
HIF-1α polymorphisms and clinicopathological parameters in 
colorectal cancer, we did not identify a correlation between the 
HIF-1α polymorphisms and any of the pretreatment parameters 
(26,28). Knechtel et al reported that the HIF-1α G1790A GA/
AA genotype was associated with localisation in the rectum 
and a higher T category (28); however, similar to Kang et al, 
the authors identified no correlation between HIF‑1α C1772T 
and clinicopathological parameters (19). With a small HIF‑1α 
G1790A GA/AA frequency of 11/341 in their population and 
1/65 in our cohort, it is difficult to make a qualified compar-
ison. Fransen et al identified an association between ulcerative 
tumours and the variant allele of the HIF-1α C1772T or HIF-1α 
G1790A in 198 CRC patients; however, no correlation between 
the other clinicopathological parameters was observed (26).
In the present study, we identified a marginal association 
between T‑containing genotypes of HIF‑1α c*191T>C and 
poor response to CRT in the test cohort. However, this could 
not be confirmed in the validation cohort, which demonstrated 
a significantly opposing effect. The results presented in this 
study underline the importance of validation studies. The 
literature on biomarkers is characterised by a high number 
of small ‘positive’ studies, which are never validated in new 
prospective patient materials, and the risk of small ‘positive’ 
studies demonstrating a false positive is extremely high (34).
The two cohorts in this study varied with regards to the 
pre-treatment cT/cN category and the type of radiotherapy 
administered. The test cohort included patients from two 
previously published studies of which one solely included 
T3 tumours. This explains the differences in the cT category. 
Additionally, a difference in lymph node metastasis pre-treat-
ment evaluation was observed between the two cohorts, but 
Table III. TRG 1 and CPR according to HIF‑1α c*191T>C.
 TRG 1 TRG 2-4 CPR+ CPR-
Polymorphism and ----------------------- ---------------------- ---------------------- -----------------------
genotype n % n % P-value n % n % P-value
Test cohort
  HIF-1α c*191T>C CC 18 35 33 65 0.05 15 29 36 71 0.16
  HIF-1α c*191T>C CT/TT 1 7 13 93  1 7 13 93
Total 19  46   16  49
Validation cohort
  HIF-1α c*191T>C CC 25 16 128 84 0.03 24 16 129 84 0.19
  HIF-1α c*191T>C CT/TT 14 31 31 69  11 24 34 76
Total 39  159   35  163
TRG, tumour regression grade; CPR, complete pathological response; HIF‑1α, hypoxia‑inducible factor‑1α.
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no difference was observed in the lymph node metastasis 
post-treatment pathological evaluation. All patients of the test 
cohort received brachytherapy, while only half of the patients 
in the validation cohort received brachytherapy. However, in 
the validation cohort there was no difference in the associa-
tion of the polymorphism and the response to CRT between 
patients receiving brachytherapy and those who did not. These 
minor differences between the cohorts are unlikely to explain 
the various results on tumour response in the two cohorts. 
Therefore, a clinically relevant predictive role of the polymor-
phisms with regards to neoadjuvant CRT of rectal cancer is 
dubious.
In conclusion, we were unable to find any predictive value 
of the HIF-1α C1772T, HIF-1α G1790A and HIF-1α c*191T>C 
polymorphisms with regards to tumour response following 
neoadjuvant CRT of locally advanced rectal cancer.
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